AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 292: R743-R750, 2007. First published August 3, 2006; doi:10.1152/ajpregu.00373.2006
0363-6119/07 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/2/R743    most recent
00373.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rayner, K.
Right arrow Articles by O'Brien, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rayner, K.
Right arrow Articles by O'Brien, E. R.

CALL FOR PAPERS
Sex Differences in Renal and Cardiovascular Function: Physiology and Pathophysiology

NM23-H2, an estrogen receptor beta-associated protein, shows diminished expression with progression of atherosclerosis

Katey Rayner,1 Yong-Xiang Chen,1 Benjamin Hibbert,1 Dawn White,1 Harvey Miller,1 Edith H. Postel,2 and Edward R. O'Brien1

1University of Ottawa Heart Institute, Ottawa, Ontario, Canada; and 2Robert Wood Johnson Medical School, New Brunswick, New Jersey

Submitted 31 May 2006 ; accepted in final form 1 August 2006

While estrogen receptor (ER) profile plays an important role in response to estrogens, receptor coregulators act as critical determinants of signaling. Although the clinical effects of ovarian hormones on various normal and pathological processes are an active area of research, the exact signaling effects on, for example, the vessel wall, are incompletely understood. Hence, we sought to discover proteins that associate with ERbeta, the isoform that shows upregulated mRNA expression after arterial injury. Using a yeast two-hybrid screen we identified NM23-H2, a multifaceted metastasis suppressor candidate protein, as an ERbeta-associated protein. Although NM23-H2 was immunodetected in arteries from young subjects (27 ± 6 yr, 14 men and 6 women) with benign intimal hyperplasia, expression was diminished in fatty streaks/atheromas and altogether absent in advanced atherosclerotic lesions. Both nm23-H2 mRNA and protein were expressed by vascular cells in vitro. Treatment with 17beta-estradiol and an ERbeta-selective agonist, diarylpropionitrile, increased protein expression of NM23-H2; an effect that was not seen with an ER{alpha}-selective agonist, propylpyrazole-triol. Estrogen also prompted nuclear localization of NM23-H2 protein in human coronary smooth muscle cells (SMCs). An in vitro mimic of inflammation decreased the expression of NM23-H2 in SMCs, which was restored on addition of estrogen and dependent on the estrogen receptor. In summary, we report the novel association of NM23-H2 with ERbeta and show for the first time its expression in vascular cells and demonstrate regulation of its expression and localization by estrogen. In that the abundance of NM23-H2 diminishes with both the advancement of atherosclerosis and inflammation, this ERbeta-associated protein may play an important role in mediating the vasculoprotective effects of estrogens.

atherosclerosis; receptors



Address for reprint requests and other correspondence: Edward O'Brien, Vascular Biology Laboratory, Division of Cardiology, Rm. H-263, Univ. of Ottawa Heart Institute, Ottawa, ON, Canada K1Y4W7 (e-mail: eobrien{at}ottawaheart.ca)




This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
K. Denton and C. Baylis
Physiological and molecular mechanisms governing sexual dimorphism of kidney, cardiac, and vascular function
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R697 - R699.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.